Evidence map›Paper›PMID 31925340›Full record

Trial reportHypertension research : official journal of the Japanese Society of Hypertension2020

Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC).

Atsushi Tanaka, Makoto Suzuki, Kazuo Matsunaga, Isao Taguchi, Shiro Nakahara, Atsuko Chihara, Jun-Ichi Oyama, Koichi Node

Abstract readLetterRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Hypertension research : official journal of the Japanese Society of Hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Atsushi TanakaDepartment of Cardiovascular Medicine, Saga University, Saga, Japan. tanakaa2@cc.saga-u.ac.jp.
Makoto SuzukiDepartment of Cardiology, Yokohama Minami Kyosai Hospital, Yokohama, Japan.
Kazuo MatsunagaDepartment of Internal Medicine, Imari-Arita Kyoritsu Hospital, Matsuura, Japan.
Isao TaguchiDepartment of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Shiro NakaharaDepartment of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Atsuko ChiharaDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.
Jun-Ichi OyamaDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Japan. node@cc.saga-u.ac.jp.
Saga University · JPSocial Insurance Saitama Chuo Hospital · JPImari Arita Kyoritsu Hospital · JPYokohama Minami Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAlbuminuriaAtrial FibrillationFactor Xa InhibitorsFemaleHumansMaleMiddle AgedRenal Insufficiency, ChronicRivaroxabanFactor Xa InhibitorsRivaroxaban

Identifiers

PMID31925340
OpenAlexW2999543638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.